Hutchinson-Gilford Progeria Treatment Market 2021 Detailed in Latest Research Study, Business Growth Strategies, and Analysis Report 2021-2028

Market Overview

A genetic condition characterized by accelerated aging in children is called Hutchinson-Gilford Progenitor Syndrome (HGPS). The name of the condition comes from the Greek word, progeria, meaning "prematurely old." This disorder is fatal, and the symptoms can be fatal. This disease is caused by a mutation in the LMNA gene. A defective LMNA protein causes the nuclear membrane of a cell to become unstable and degraded, leading to cellular instability and premature aging. The gene causing Hutchinson-Gilford progeria syndrome is located on chromosome 1q, within an interval of chromosome 1. Although the genes responsible for this condition are rare, they are very similar to those responsible for accelerated aging.

Get the complete sample, please click: https://www.coherentmarketinsights.com/insight/request-sample/35

Market Dynamics

Increasing prevalence of Hutchinson-Gilford progeria is expected to drive growth of the global Hutchinson-Gilford progeria market during the forecast period. Hutchinson-Gilford progeria is very, very rare genetic disorder and according to the National Organization for Rare Disorders (NORD), HGPS affect around 1 in 20 million children. Therefore, at a given time, there are around 400 children living with progeria. Furthermore, according to the Progeria Research Foundation International Progeria Registry, as of December 2020, around 131 children and young adults have been identified with progeria with 20 of them living in the U.S. As a result of this, the demand for adequate treatment options has increased.

However, a lack of awareness in emerging economies regarding treatment options is expected to hinder the global Hutchinson-Gilford progeria treatment market growth over the forecast period.

Impact of COVID-19 Pandemic

The global Hutchinson-Gilford progeria treatment witnessed a major negative impact due to the outbreak of the COVID-19 pandemic in December 2019. Following the outbreak in China, countries across the globe decided to implement nationwide lockdown policies, in order to curb the spread of the virus. Such policies led to a major decline in economic activities, hampering growth of the market in the discussion. Furthermore, the massive disruption in the global supply chain industry also has an impact on growth of the market.

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/35

Key Takeaways

• The global Hutchinson-Gilford progeria treatment is expected to witness robust growth, exhibiting a CAGR of 7.7% over the forecast period. This is owing to introduction of novel therapies. For instance, in November 2020, Eiger BioPharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for Zokinvy capsules to reduce the risk of death due to the Hutchinson-Gilford progeria syndrome.

• Among regions, North America is expected to witness significant growth in the global Hutchinson-Gilford progeria market during the forecast period. This is owing to robust healthcare infrastructure, high disposable income, and ongoing research activities across the region.

• Key players involved in the global Hutchinson-Gilford progeria treatment market are Eiger BioPharmaceuticals, Teva Pharmaceutical, Inc., Amgen, Sanofi, and Novartis AG.

1001 4th Ave, #3200 Seattle, WA 98154, United States.Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights :

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.